Role of 18 F-FDG PET/CT in primary brain lymphoma

de-Bonilla-Damiá, Á.; Fernández-López, Rosa; Capote-Huelva, F.J.; Cruz-Vicente, Fátima de la; Egea-Guerrero, Juan José; Borrego-Dorado, I.

doi:10.1016/j.remnie.2017.07.002

Cited by 4 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies [9][10][11][12] have reported good diagnostic utility of FDG-PET/CT in differentiating PCNSL from morphologically similar lesions on conventional neuro-imaging such as highgrade gliomas and brain metastases. CNS lymphomas generally demonstrate high FDG-avidity with a mean SUVmax about 2.5 times higher than the average uptake in the normal uninvolved gray matter.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic Performance of Baseline 18F-Fluoro-Deoxy- Glucose Positron Emission Tomography/Computed Tomography in Patients with Clinico-Radiological Suspicion of Primary Central Nervous System Lymphoma

Gupta¹

2019

Ann Hematol Oncol

View full text Add to dashboard Cite

Background: Morphological features of Primary Central Nervous System Lymphoma (PCNSL) have considerable overlap with other common intra-cranial lesions such as high-grade glioma, brain metastasis, and infection/inflammation on Magnetic Resonance Imaging (MRI) rendering pre-operative diagnosis difficult. We hypothesized that significantly higher uptake in PCNSL compared to other lesions on baseline 18F-Flouro-Deoxy-Glucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) would allow more accurate and reliable diagnosis.Methods: Adult patients with a differential diagnosis of PCNSL on conventional neuro-imaging underwent pre-biopsy whole-body FDG-PET/CT after written informed consent followed by planned neuro-surgical intervention for confirmation of diagnosis at a single institute. All pre-treatment FDG-PET/ CT scans were reviewed and interpreted independently by a senior imaging specialist in an unbiased manner, who reported the 'likely' diagnosis on FDG-PET/CT blinded to final histo-pathology. Diagnostic performance of baseline FDG-PET/CT was calculated using pathological diagnosis as the reference standard.Results: Twenty-six of 45 patients were diagnosed as having CNS lymphoma (including 3 with systemic lymphoma), while remaining 19 patients were deemed to have 'non-lymphomatous' lesions such as high-grade glioma, brain metastasis, infection/inflammation on pre-treatment FDG-PET/CT. The sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy of qualitative FDG-PET/CT with 95% confidence interval (95% CI) in the diagnosis of PCNSL (excluding 3 patients with systemic lymphoma) was 77.4% (95% CI=54.6-92.2%); 70% (95% CI=45.7-88.1%), 73.9% (95% CI=58.3-85.2%), 73.7% (95% CI=55.2-86.4%), and 73.8% (95% CI=58-86.1%) respectively. Conclusions:Baseline FDG-PET/CT has acceptable diagnostic accuracy (adjunctive to MRI) in suspected PCNSL, particularly in patients with deepseated lesions not amenable to a safe neuro-surgical biopsy.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic Performance of Baseline 18F-Fluoro-Deoxy- Glucose Positron Emission Tomography/Computed Tomography in Patients with Clinico-Radiological Suspicion of Primary Central Nervous System Lymphoma

Gupta¹

2019

Ann Hematol Oncol

View full text Add to dashboard Cite

show abstract

“…18 F-FDG PET is a useful imaging technique for monitoring response, mostly for methotrexate-based treatments, and detection of recurrence. 16 It has shown overall high accuracy in predicting treatment outcome in CNS lymphoma, both during and after completion of treatment. 17 It can be used to evaluate treatment response of PCNSL at early stage as changes in metabolic imaging occur soon after the initiation of therapy (Figure 2).…”

Section: Literature Reviewmentioning

confidence: 99%

The role of 18F-FDG PET/CT in evaluation of Primary CNS lymphoma: The path less travelled

Sharjeel Usmani,

Anjali Jain,

Khulood Al Riyami

et al. 2023

J Pak Med Assoc

View full text Add to dashboard Cite

Primary central nervous system lymphoma (PCNSL) is a rare but highly aggressive lymphoma with increasing incidence in immunocompromised patients. MRI is the modality of choice in evaluating brain lesions. However, MRI is often challenging in the detection of early recurrence, assessing residual disease and response evaluation in PCNSL. 18F-FDG PET/CT has superior diagnostic performance compared with body CT in the evaluation of lymphoma. 18F-FDG PET-CT is helpful in evaluating evaluation of disease extent and differentiating primary CNS lymphoma from systemic lymphoma. Besides diagnostic and prognostic value in primary CNS lymphoma, it might also be helpful in response assessment. The role of FDG-PET in PCNSL is not fully defined. In this article we have reviewed the potential role of 18F-FDG PET/CT in initial diagnosis, baseline staging, restaging, evaluation of treatment response, prognostication, and survival analysis of PCNSL. Keywords: 18F-FDG PET/CT; CNS lymphoma; brain tumors.

show abstract

“…At present, conventional MRI evaluates the response of PCNSL to radiotherapy and chemotherapy according to the change in lesion size on T1WI after treatment [ 7 ]. In recent years, some scholars have found that after a large dose of methotrexate chemotherapy, if the MRI-enhanced scan lesions are evenly enhanced, then patients with PCNSL have a better prognosis, but the prognosis of patients with intensified intensification is generally poor [ 8 ]. Some scholars have found that after PCNSL patients undergo chemotherapy and MRI scan, if the TlWl signal of the lesion increases, it indicates that the tumor cells respond to the treatment.…”

Section: Introductionmentioning

confidence: 99%

“…The enhancement of PCNSL only reflects the degree of damage of the blood-brain barrier and does not reflect the degree of tumor angiogenesis. Because PCNSL lesion itself has no obvious blood supply, PWI showed a low perfusion mass, cerebral blood volume and cerebral blood flow decreased, average passage time and peak time prolonged, which was significantly different from high perfusion of high-grade glioma [ 8 ]. In recent years, studies have shown that CBV values without contrast-deficient correction are the best indicators for identifying PCNSL and gliomas by PWI.…”

Section: Introductionmentioning

confidence: 99%

Intelligent Diagnosis and Analysis of Brain Lymphoma Based on DSC Imaging Features

Mao

Jiang

Zhao³

2022

Computational Intelligence and Neuroscience

View full text Add to dashboard Cite

Currently, DSC has been extensively studied in the diagnosis, differential diagnosis, and prognosis evaluation of brain lymphoma, but it has not obtained a uniform standard. By combining DSC imaging features, this study investigated the imaging features and diagnostic value of several types of tumors such as primary brain lymphoma. At the same time, this study obtained data from brain lymphoma patients by data collection and set up different groups to conduct experimental studies to explore the correlation between IVIMMRI perfusion parameters and DSC perfusion parameters in brain lymphoma. Through experimental research, it can be seen that the combination of two perfusion imaging techniques can more fully reflect the blood flow properties of the lesion, which is beneficial to determine the nature of the lesion.

show abstract

Role of 18 F-FDG PET/CT in primary brain lymphoma

Cited by 4 publications

References 19 publications

Diagnostic Performance of Baseline 18F-Fluoro-Deoxy- Glucose Positron Emission Tomography/Computed Tomography in Patients with Clinico-Radiological Suspicion of Primary Central Nervous System Lymphoma

Diagnostic Performance of Baseline 18F-Fluoro-Deoxy- Glucose Positron Emission Tomography/Computed Tomography in Patients with Clinico-Radiological Suspicion of Primary Central Nervous System Lymphoma

The role of 18F-FDG PET/CT in evaluation of Primary CNS lymphoma: The path less travelled

Intelligent Diagnosis and Analysis of Brain Lymphoma Based on DSC Imaging Features

Contact Info

Product

Resources

About